Isoquercetin (Synonyms: NSC 115918, Quercetin 3-β-D-glucoside, Quercetin 3-O-glucoside) |
Catalog No.GC41273
One-Click Copy Product Info
|
Isoquercetin is a flavonoid with diverse biological activities, including antioxidant, antiproliferative, and anti-inflammatory properties.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 482-35-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Isoquercetin is a flavonoid with diverse biological activities, including antioxidant, antiproliferative, and anti-inflammatory properties[1, 2]. Due to its high bioavailability and low toxicity, Isoquercetin is a promising candidate for preventing congenital defects in diabetic pregnancy[3].
In vitro, pretreatment of primary cultured rat cortical neurons with Isoquercetin (20, 40, 80µg/mL) for 24h reduced the increase in intracellular calcium concentration and lactate dehydrogenase (LDH) release induced by oxygen-glucose deprivation/reperfusion (OGD/R) injury, and prevented the decrease in cell viability[4]. Pretreatment of HepG2 cells with Isoquercetin (10μM) for 1h significantly downregulated ethanol-induced iNOS protein expression levels in the cells[5].
In vivo, intravenous administration of Isoquercetin (50mg/kg) for 7 days to rats subjected to middle cerebral artery occlusion (MCAO) injury reduced the cerebral infarct volume and mitigated the decrease in Nrf2 expression levels in hippocampal tissue[6]. Oral administration of Isoquercetin (20mg/kg) for 3 days to rats subjected to middle cerebral artery occlusion/reperfusion (MCAO/R) injury reduced the cerebral infarct volume, improved neurological deficits, and decreased the production of reactive oxygen species (ROS) and malondialdehyde (MDA) in brain tissue[7].
References:
[1] Mbikay M, Chrétien M. Isoquercetin as an anti-COVID-19 medication: A potential to realize[J]. Frontiers in Pharmacology, 2022, 13: 830205.
[2] Azeem M, Hanif M, Mahmood K, et al. An insight into anticancer, antioxidant, antimicrobial, antidiabetic and anti-inflammatory effects of quercetin: A review[J]. Polymer Bulletin, 2023, 80(1): 241-262.
[3] Cao L, Tan C, Meng F, et al. Amelioration of intracellular stress and reduction of neural tube defects in embryos of diabetic mice by phytochemical quercetin[J]. Scientific Reports, 2016, 6(1): 21491.
[4] Wang C P, Li J L, Zhang L Z, et al. Isoquercetin protects cortical neurons from oxygen–glucose deprivation–reperfusion induced injury via suppression of TLR4–NF-кB signal pathway[J]. Neurochemistry international, 2013, 63(8): 741-749.
[5] Lee S, Lee J, Lee H, et al. Relative protective activities of quercetin, quercetin‐3‐glucoside, and rutin in alcohol‐induced liver injury[J]. Journal of food biochemistry, 2019, 43(11): e13002.
[6] Chen M, Dai L H, Fei A, et al. Isoquercetin activates the ERK1/2-Nrf2 pathway and protects against cerebral ischemia-reperfusion injury in vivo and in vitro[J]. Experimental and Therapeutic Medicine, 2017, 13(4): 1353-1359.
[7] Dai Y, Zhang H, Zhang J, et al. Isoquercetin attenuates oxidative stress and neuronal apoptosis after ischemia/reperfusion injury via Nrf2-mediated inhibition of the NOX4/ROS/NF-κB pathway[J]. Chemico-biological interactions, 2018, 284: 32-40.
| Cell experiment [1]: | |
Cell lines | Primary culture of rat cortical neurons |
Preparation Method | The primary culture of rat cortical neurons were pretreated with 20, 40 and 80µg/mL Isoquercetin and 2.5, 5µg/mL nimodipine, respectively, for 24h, followed by exposure to oxygen-glucose deprivation (OGD) for 6h, then reperfusion for 24h. The cortical neurons cultured in plain medium served as control. |
Reaction Conditions | 20, 40, 80µg/mL; 24h |
Applications | Isoquercetin administered prior to the insult could prevent OGD/R-induced intracellular calcium concentrations ([Ca2+]i) increase, lactate dehydrogenase (LDH) release and cell viability decrease. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley (SD) rats |
Preparation Method | The rats were randomly allocated to one of four groups: Control, sham, model and Isoquercetin. In the model group, rats were anesthetized via the intraperitoneal injection of 10% chloral hydrate. The rectal temperature was monitored and maintained at 37.0±0.5˚C by the use of a feedback‑regulated heating system during surgery. Permanent focal ischemia was induced by occluding the right middle cerebral artery (MCA) via an intraluminal technique. Briefly, a 4‑0 nylon monofilament suture with a slightly enlarged rounded tip was inserted into the stump of the external carotid artery and advanced into the lumen of the internal carotid artery until it reached and occluded the MCA. The distance from the bifurcation of the common carotid artery (CCA) to the tip of the inserted suture averaged 18‑20mm. Sham operated animals were subjected to the aforementioned procedures, with the exception of suture insertion. Rats in the Isoquercetin group were subjected to MCAO surgery and treated with intravenous 50mg/kg Isoquercetin once a day for 7 days. Rats that did not undergo any surgery served as the control group. |
Dosage form | 50mg/kg; 7 days; i.v. |
Applications | The rats treated with Isoquercetin exhibited a lower degree of neurological dysfunction and smaller infarct volume than the vehicle‑treated rats. In the hippocampal tissue, the expression of Nrf2 at the mRNA and protein levels was decreased in the model group 7 days after ischemia, and the reduction in expression levels was significantly attenuated in the Isoquercetin treated-group. |
References: | |
| Cas No. | 482-35-9 | SDF | |
| Synonyms | NSC 115918, Quercetin 3-β-D-glucoside, Quercetin 3-O-glucoside | ||
| Canonical SMILES | OC1=CC(O)=C(C(C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)=C(C3=CC=C(O)C(O)=C3)O4)=O)C4=C1 | ||
| Formula | C21H20O12 | M.Wt | 464.4 |
| Solubility | DMF: 10 mg/ml,DMSO: 10 mg/ml,PBS (pH 7.2): 0.3 mg/ml | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1533 mL | 10.7666 mL | 21.5332 mL |
| 5 mM | 430.7 μL | 2.1533 mL | 4.3066 mL |
| 10 mM | 215.3 μL | 1.0767 mL | 2.1533 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)